206 related articles for article (PubMed ID: 34383966)
41. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
42. Meta-analysis: Barrett's oesophagus and the risk of colonic tumours.
Andrici J; Tio M; Cox MR; Eslick GD
Aliment Pharmacol Ther; 2013 Feb; 37(4):401-10. PubMed ID: 23163592
[TBL] [Abstract][Full Text] [Related]
43. [Surveillance for Barrett's oesophagus: worthwhile?].
Kastelein F; Kuipers EJ
Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
[TBL] [Abstract][Full Text] [Related]
44. Chemoprevention in Barrett's oesophagus.
Baruah A; Buttar NS
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):151-65. PubMed ID: 25743463
[TBL] [Abstract][Full Text] [Related]
45. Systematic review with meta-analysis: neoplasia detection rate and post-endoscopy Barrett's neoplasia in Barrett's oesophagus.
Hamade N; Kamboj AK; Krishnamoorthi R; Singh S; Hassett LC; Katzka DA; Kahi CJ; Fatima H; Iyer PG
Aliment Pharmacol Ther; 2021 Sep; 54(5):546-559. PubMed ID: 34275161
[TBL] [Abstract][Full Text] [Related]
46. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue.
Choi WT; Tsai JH; Rabinovitch PS; Small T; Huang D; Mattis AN; Kakar S
Gut; 2018 Jul; 67(7):1229-1238. PubMed ID: 28642331
[TBL] [Abstract][Full Text] [Related]
47. A family history of Barrett's oesophagus: another risk factor?
Groves C; Jankowski J; Barker F; Holdstock G
Scand J Gastroenterol; 2005 Sep; 40(9):1127-8. PubMed ID: 16211720
[TBL] [Abstract][Full Text] [Related]
48. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
49. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Gatenby P; Caygill C; Wall C; Bhatacharjee S; Ramus J; Watson A; Winslet M
World J Gastroenterol; 2014 Jul; 20(28):9611-7. PubMed ID: 25071359
[TBL] [Abstract][Full Text] [Related]
50. Dutch individuals' views of screening for oesophageal cancer: a focus group study.
Sijben J; Peters Y; Bas S; Siersema P; Rainey L; Broeders M
BMJ Open Gastroenterol; 2023 May; 10(1):. PubMed ID: 37257920
[TBL] [Abstract][Full Text] [Related]
51. Barrett's oesophagus: Current controversies.
Amadi C; Gatenby P
World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
[TBL] [Abstract][Full Text] [Related]
52. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C
Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177
[TBL] [Abstract][Full Text] [Related]
53. Developing patient-orientated Barrett's oesophagus services: the role of dedicated services.
Ratcliffe E; Britton J; Hamdy S; McLaughlin J; Ang Y
BMJ Open Gastroenterol; 2022 Feb; 9(1):. PubMed ID: 35193888
[TBL] [Abstract][Full Text] [Related]
54. Active human papillomavirus involvement in Barrett's dysplasia and oesophageal adenocarcinoma is characterized by wild-type p53 and aberrations of the retinoblastoma protein pathway.
Rajendra S; Yang T; Xuan W; Sharma P; Pavey D; Lee CS; Le S; Collins J; Wang B
Int J Cancer; 2017 Nov; 141(10):2037-2049. PubMed ID: 28722212
[TBL] [Abstract][Full Text] [Related]
55. Oesophageal adenocarcinoma and Barrett's oesophagus.
Das M
Lancet Oncol; 2016 Dec; 17(12):e524. PubMed ID: 27818151
[No Abstract] [Full Text] [Related]
56. Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
Iwaya Y; Hasebe O; Koide N; Kitahara K; Suga T; Shinji A; Muraki T; Yokosawa S; Yamada S; Arakura N; Tanaka E; Nakayama J
Histopathology; 2014 Mar; 64(4):536-46. PubMed ID: 24117499
[TBL] [Abstract][Full Text] [Related]
57. Dissecting the genetic heterogeneity of gastric cancer.
Hess T; Maj C; Gehlen J; Borisov O; Haas SL; Gockel I; Vieth M; Piessen G; Alakus H; Vashist Y; Pereira C; Knapp M; Schüller V; Quaas A; Grabsch HI; Trautmann J; Malecka-Wojciesko E; Mokrowiecka A; Speller J; Mayr A; Schröder J; Hillmer AM; Heider D; Lordick F; Pérez-Aísa Á; Campo R; Espinel J; Geijo F; Thomson C; Bujanda L; Sopeña F; Lanas Á; Pellisé M; Pauligk C; Goetze TO; Zelck C; Reingruber J; Hassanin E; Elbe P; Alsabeah S; Lindblad M; Nilsson M; Kreuser N; Thieme R; Tavano F; Pastorino R; Arzani D; Persiani R; Jung JO; Nienhüser H; Ott K; Schumann RR; Kumpf O; Burock S; Arndt V; Jakubowska A; Ławniczak M; Moreno V; Martín V; Kogevinas M; Pollán M; Dąbrowska J; Salas A; Cussenot O; Boland-Auge A; Daian D; Deleuze JF; Salvi E; Teder-Laving M; Tomasello G; Ratti M; Senti C; De Re V; Steffan A; Hölscher AH; Messerle K; Bruns CJ; Sīviņš A; Bogdanova I; Skieceviciene J; Arstikyte J; Moehler M; Lang H; Grimminger PP; Kruschewski M; Vassos N; Schildberg C; Lingohr P; Ridwelski K; Lippert H; Fricker N; Krawitz P; Hoffmann P; Nöthen MM; Veits L; Izbicki JR; Mostowska A; Martinón-Torres F; Cusi D; Adolfsson R; Cancel-Tassin G; Höblinger A; Rodermann E; Ludwig M; Keller G; Metspalu A; Brenner H; Heller J; Neef M; Schepke M; Dumoulin FL; Hamann L; Cannizzaro R; Ghidini M; Plaßmann D; Geppert M; Malfertheiner P; Gehlen O; Skoczylas T; Majewski M; Lubiński J; Palmieri O; Boccia S; Latiano A; Aragones N; Schmidt T; Dinis-Ribeiro M; Medeiros R; Al-Batran SE; Leja M; Kupcinskas J; García-González MA; Venerito M; Schumacher J
EBioMedicine; 2023 Jun; 92():104616. PubMed ID: 37209533
[TBL] [Abstract][Full Text] [Related]
58. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.
Conio M; Cameron AJ; Romero Y; Branch CD; Schleck CD; Burgart LJ; Zinsmeister AR; Melton LJ; Locke GR
Gut; 2001 Mar; 48(3):304-9. PubMed ID: 11171817
[TBL] [Abstract][Full Text] [Related]
59. The characterization of an intestine-like genomic signature maintained during Barrett's-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival.
Duggan SP; Behan FM; Kirca M; Zaheer A; McGarrigle SA; Reynolds JV; Vaz GM; Senge MO; Kelleher D
Sci Rep; 2016 Sep; 6():32638. PubMed ID: 27586588
[TBL] [Abstract][Full Text] [Related]
60. The '-omics' revolution and oesophageal adenocarcinoma.
Weaver JM; Ross-Innes CS; Fitzgerald RC
Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):19-27. PubMed ID: 23982683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
